Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer

Cynthia Ma, MD, PhD
Published: Thursday, Jul 28, 2016



Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer (TNBC).

The METRIC trial is a randomized study comparing glembatumumab vedotin (CDX-011), a gpNMB-targeted antibody-drug conjugate, with capecitabine in patients with metastatic TNBC.

Patients are being randomized in a 2:1 ratio to receive glembatumumab vedotin or capecitabine. The study is selecting patients who are positive for gpNMB, which is present in about 40% of TNBC cases. Initial preliminary data have shown that patients with TNBC may have longer progression-free survival when they have increased gpNMB expression.


Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer (TNBC).

The METRIC trial is a randomized study comparing glembatumumab vedotin (CDX-011), a gpNMB-targeted antibody-drug conjugate, with capecitabine in patients with metastatic TNBC.

Patients are being randomized in a 2:1 ratio to receive glembatumumab vedotin or capecitabine. The study is selecting patients who are positive for gpNMB, which is present in about 40% of TNBC cases. Initial preliminary data have shown that patients with TNBC may have longer progression-free survival when they have increased gpNMB expression.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x